LV10179B - Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them - Google Patents

Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them Download PDF

Info

Publication number: LV10179B
Authority: LV; Latvia
Prior art keywords: melphalan; hydrochloride; component; citrate; solvent
Prior art date: 1987-11-19

Application number

LVP-93-1379A

Other languages

English (en)

Latvian (lv)

Other versions

LV10179A (lv

Inventor

Poole Stephen William

Stanley Timothy Paul

Divall Geoffrey

Packham Terence William

Knight Joseph

Original Assignee

Wellcome Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-19

Filing date

1993-12-28

Publication date

1995-06-20

1993-12-28 Application filed by Wellcome Found filed Critical Wellcome Found

1994-10-20 Publication of LV10179A publication Critical patent/LV10179A/xx

1995-06-20 Publication of LV10179B publication Critical patent/LV10179B/en

Links

SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 title claims abstract description 59
229960001924 melphalan Drugs 0.000 title claims abstract description 52
OUUYBRCCFUEMLH-YDALLXLXSA-N [(1s)-2-[4-[bis(2-chloroethyl)amino]phenyl]-1-carboxyethyl]azanium;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 OUUYBRCCFUEMLH-YDALLXLXSA-N 0.000 title claims abstract description 26
229960002514 melphalan hydrochloride Drugs 0.000 title claims abstract description 26
238000000034 method Methods 0.000 title claims description 13
239000008194 pharmaceutical composition Substances 0.000 title abstract description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 33
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 13
238000002360 preparation method Methods 0.000 claims abstract description 12
239000000203 mixture Substances 0.000 claims description 32
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
239000003085 diluting agent Substances 0.000 claims description 15
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 5
229910000041 hydrogen chloride Inorganic materials 0.000 claims description 5
238000001816 cooling Methods 0.000 claims description 4
238000002425 crystallisation Methods 0.000 claims description 4
230000008025 crystallization Effects 0.000 claims description 4
238000010438 heat treatment Methods 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
-1 alkali metal citrate Chemical class 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 2
229910052783 alkali metal Inorganic materials 0.000 claims 1
125000001475 halogen functional group Chemical group 0.000 claims 1
229960004063 propylene glycol Drugs 0.000 abstract 1
235000013772 propylene glycol Nutrition 0.000 abstract 1
238000009472 formulation Methods 0.000 description 19
239000000243 solution Substances 0.000 description 15
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
239000008215 water for injection Substances 0.000 description 7
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
239000007972 injectable composition Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
206010033128 Ovarian cancer Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000001914 filtration Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
229940098174 alkeran Drugs 0.000 description 3
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
229940069328 povidone Drugs 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000001509 sodium citrate Substances 0.000 description 3
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
239000007787 solid Substances 0.000 description 3
208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
208000034578 Multiple myelomas Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000003513 alkali Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
238000005660 chlorination reaction Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
238000011049 filling Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000021712 Soft tissue sarcoma Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Inorganic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Catalysts (AREA)
Steroid Compounds (AREA)

LVP-93-1379A 1987-11-19 1993-12-28 Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them LV10179B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB878727157A GB8727157D0 (en)	1987-11-19	1987-11-19	Pharmaceutical formulations
EP88310805A EP0317281B1 (fr)	1987-11-19	1988-11-16	Formulations pharmaceutiques contenant du melphalan ou du chlorhydrate de melphalan, le melphalan et le chlorhydrate de melphalan et procédés pour les préparer

Publications (2)

Publication Number	Publication Date
LV10179A LV10179A (lv)	1994-10-20
LV10179B true LV10179B (en)	1995-06-20

Family

ID=10627252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-1379A LV10179B (en)	1987-11-19	1993-12-28	Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them

Country Status (22)

Country	Link
US (1)	US4997651A (fr)
EP (1)	EP0317281B1 (fr)
JP (1)	JP2693191B2 (fr)
KR (1)	KR970002607B1 (fr)
AT (1)	ATE83922T1 (fr)
AU (1)	AU619781B2 (fr)
CA (1)	CA1341114C (fr)
DE (1)	DE3877151T2 (fr)
DK (1)	DK172794B1 (fr)
ES (1)	ES2052745T3 (fr)
FI (2)	FI90204C (fr)
GB (1)	GB8727157D0 (fr)
GR (1)	GR3007287T3 (fr)
HK (1)	HK108994A (fr)
HU (3)	HU207286B (fr)
IE (1)	IE63996B1 (fr)
IL (1)	IL88419A (fr)
LV (1)	LV10179B (fr)
NZ (2)	NZ227004A (fr)
PT (1)	PT89028B (fr)
SG (1)	SG73894G (fr)
ZA (1)	ZA888674B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5695751A (en) *	1993-04-08	1997-12-09	Cornell Research Foundation, Inc.	Enhancing delivery of large neutral amino acid drugs
US5407672A (en) *	1993-04-08	1995-04-18	Cornell Research Foundation, Inc.	Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase
US6020004A (en) *	1997-04-17	2000-02-01	Amgen Inc.	Biodegradable microparticles for the sustained delivery of therapeutic drugs
US5980904A (en) *	1998-11-18	1999-11-09	Amway Corporation	Skin whitening composition containing bearberry extract and a reducing agent
GB2386066A (en) *	2002-02-28	2003-09-10	Norbrook Lab Ltd	Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species
JP2005535626A (ja) *	2002-06-24	2005-11-24	リサーチ　ディベロップメント　ファンデーション	クルクミンによるヒト多発性骨髄腫の治療
US7462646B2 (en)	2003-08-26	2008-12-09	Research Development Foundation	Osteoclastogenesis inhibitors and uses thereof
US7872050B2 (en)	2005-03-14	2011-01-18	Yaupon Therapeutics Inc.	Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en)	2005-03-14	2013-08-06	Ceptaris Therapeutics, Inc.	Stabilized compositions of alkylating agents and methods of using same
LT2273876T (lt)	2008-03-27	2019-05-27	Helsinn Healthcare Sa	Stabilizuotos alkilinimo medžiagų kompozicijos ir jų panaudojimo būdai
AR066943A1 (es) *	2008-06-10	2009-09-23	Eriochem Sa	Una composicion farmaceutica de melfalano
US11020363B2 (en)	2009-05-29	2021-06-01	Cydex Pharmaceuticals, Inc.	Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
MX388477B (es)	2009-05-29	2025-03-12	Cydex Pharmaceuticals Inc	Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de fabricación y uso de las mismas.
AR077384A1 (es)	2010-07-05	2011-08-24	Eriochem Sa	Una formulacion farmaceutica inyectable de melfalano.
US8921596B2 (en) *	2010-11-04	2014-12-30	Emcure Pharmaceuticals, Ltd.	Process for the preparation of melphalan hydrochloride
LT2701720T (lt) *	2011-04-28	2017-11-10	Oncopeptides Ab	Liofilizuotas citotoksinių dipeptidų preparatas
KR102205592B1 (ko)	2012-10-26	2021-01-20	온코펩타이드즈 아베	멜팔란 플루펜아미드의 동결건조 제제
EP2970102B1 (fr)	2013-03-11	2019-05-08	Biophore India Pharmaceuticals Pvt. Ltd.	Procédé perfectionné pour la synthèse de melphalan et de son sel chlorhydrate
ITMI20130896A1 (it)	2013-05-31	2014-12-01	Farmabios Spa	Processo di purificazione di melphalan
CN107645954A (zh) *	2015-03-06	2018-01-30	清算中的利迪安特生物科学股份有限公司	多发性骨髓瘤的罗尼哌他组合治疗
US10537520B2 (en) *	2015-06-30	2020-01-21	Leiutis Pharmaceuticals Pvt. Ltd.	Stable liquid formulations of melphalan
EP3773498B1 (fr) *	2018-03-29	2022-06-22	Project Pharmaceutics GmbH	Formulation pharmaceutique liquide
US10682326B1 (en)	2019-06-03	2020-06-16	Shilpa Medicare Limited	Stable melphalan liquid injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB750155A (en) *	1953-03-17	1956-06-13	Nat Res Dev	Substituted alanines
US3032585A (en) *	1954-12-03	1962-05-01	Nat Res Dev	Process for the production of p-bis-(2-chloroethyl)-aminophenylalanine
DE1292660B (de) *	1963-04-24	1969-04-17	Ural Polytechnitscheskij I Im	Verfahren zur Herstellung von p-(Bis-ª‰-chloraethyl-amino)-phenylalanin-hydrochlorid
US4029778A (en) *	1969-01-23	1977-06-14	Aktiebolaget Leo	Cortical steroid nitrogen mustard compositions and treatment therewith
RO57195A2 (fr) *	1970-11-30	1974-09-01
FR2285855A1 (fr) *	1974-09-25	1976-04-23	Kohjin Co	Composition therapeutique lyophilisee a base de sel de cyclocytidine et son procede de preparation
JPS59186924A (ja) *	1983-04-08	1984-10-23	Kureha Chem Ind Co Ltd	ヒト免疫グロブリン結合抗腫瘍剤
US4696814A (en) *	1985-08-21	1987-09-29	Warner-Lambert Company	Parenteral phenytoin compositions
JPS62192357A (ja) *	1986-02-19	1987-08-22	Kureha Chem Ind Co Ltd	Ｎ−フタロイル−ｐ−ニトロ−Ｌ−フエニルアラニンの製造方法

1987
- 1987-11-19 GB GB878727157A patent/GB8727157D0/en active Pending
1988
- 1988-11-16 DE DE8888310805T patent/DE3877151T2/de not_active Expired - Lifetime
- 1988-11-16 AT AT88310805T patent/ATE83922T1/de not_active IP Right Cessation
- 1988-11-16 EP EP88310805A patent/EP0317281B1/fr not_active Expired - Lifetime
- 1988-11-16 ES ES88310805T patent/ES2052745T3/es not_active Expired - Lifetime
- 1988-11-18 NZ NZ227004A patent/NZ227004A/xx unknown
- 1988-11-18 JP JP63292228A patent/JP2693191B2/ja not_active Expired - Lifetime
- 1988-11-18 ZA ZA888674A patent/ZA888674B/xx unknown
- 1988-11-18 US US07/273,227 patent/US4997651A/en not_active Expired - Lifetime
- 1988-11-18 NZ NZ239867A patent/NZ239867A/en unknown
- 1988-11-18 HU HU91335A patent/HU207286B/hu unknown
- 1988-11-18 PT PT89028A patent/PT89028B/pt not_active IP Right Cessation
- 1988-11-18 IE IE344788A patent/IE63996B1/en not_active IP Right Cessation
- 1988-11-18 AU AU25748/88A patent/AU619781B2/en not_active Expired
- 1988-11-18 HU HU91336A patent/HU206671B/hu unknown
- 1988-11-18 CA CA000583540A patent/CA1341114C/fr not_active Expired - Fee Related
- 1988-11-18 HU HU885953A patent/HU203197B/hu unknown
- 1988-11-18 IL IL88419A patent/IL88419A/xx not_active IP Right Cessation
- 1988-11-18 DK DK198806466A patent/DK172794B1/da not_active IP Right Cessation
- 1988-11-18 KR KR1019880015196A patent/KR970002607B1/ko not_active Expired - Lifetime
- 1988-11-18 FI FI885358A patent/FI90204C/fi not_active IP Right Cessation
1992
- 1992-10-15 FI FI924668A patent/FI102275B1/fi not_active IP Right Cessation
1993
- 1993-03-09 GR GR930400510T patent/GR3007287T3/el unknown
- 1993-12-28 LV LVP-93-1379A patent/LV10179B/en unknown
1994
- 1994-06-03 SG SG73894A patent/SG73894G/en unknown
- 1994-10-06 HK HK108994A patent/HK108994A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3877151T2 (de)	1993-07-15
FI885358L (fi)	1989-05-20
HU910336D0 (en)	1991-08-28
FI102275B (fi)	1998-11-13
GB8727157D0 (en)	1987-12-23
KR970002607B1 (ko)	1997-03-06
PT89028A (pt)	1988-12-01
AU619781B2 (en)	1992-02-06
LV10179A (lv)	1994-10-20
KR890007729A (ko)	1989-07-05
GR3007287T3 (fr)	1993-07-30
EP0317281A2 (fr)	1989-05-24
ATE83922T1 (de)	1993-01-15
ES2052745T3 (es)	1994-07-16
HU207286B (en)	1993-03-29
HK108994A (en)	1994-10-14
IE63996B1 (en)	1995-06-28
FI90204C (fi)	1994-01-10
IL88419A0 (en)	1989-06-30
JPH01153628A (ja)	1989-06-15
FI924668A0 (fi)	1992-10-15
SG73894G (en)	1994-11-25
HU203197B (en)	1991-06-28
HU206671B (en)	1992-12-28
FI90204B (fi)	1993-09-30
PT89028B (pt)	1993-02-26
FI924668L (fi)	1992-10-15
HUT48198A (en)	1989-05-29
DK646688A (da)	1989-05-20
NZ227004A (en)	1992-11-25
ZA888674B (en)	1990-07-25
JP2693191B2 (ja)	1997-12-24
FI102275B1 (fi)	1998-11-13
HU9100335D0 (en)	1991-08-28
AU2574888A (en)	1989-05-25
NZ239867A (en)	1992-11-25
EP0317281A3 (en)	1989-08-09
FI885358A0 (fi)	1988-11-18
DE3877151D1 (de)	1993-02-11
DK646688D0 (da)	1988-11-18
IE883447L (en)	1989-05-19
EP0317281B1 (fr)	1992-12-30
IL88419A (en)	1993-03-15
US4997651A (en)	1991-03-05
CA1341114C (fr)	2000-10-10
DK172794B1 (da)	1999-07-19

Publication	Publication Date	Title
US4997651A (en)	1991-03-05	Pharmaceutical formulations
JP3803392B2 (ja)	2006-08-02	環式付着阻害剤
JP2928047B2 (ja)	1999-07-28	安定なポルフィマーナトリウム組成物およびその製造方法
EP4403559B1 (fr)	2026-01-28	Polymère de sesquiterpène de guaïane et procédé de préparation s'y rapportant et utilisation associée
EP0067666B1 (fr)	1985-10-30	Sels de composés microbicides de naphtyridine et quinoléine et leur préparation
JPS60188317A (ja)	1985-09-25	抗健忘症剤
RU2027442C1 (ru)	1995-01-27	Вещество, обладающее противоопухолевой активностью
AU2024219393A1 (en)	2024-09-26	Pharmaceutical composition of docetaxel conjugate and preparation method
BE1001704A3 (fr)	1990-02-13	Compositions aqueuses contenant un derive de l'acide piperidinylcyclopentylheptenoique.
HU199289B (en)	1990-02-28	Process for production of liofilized medical compositions containing derivatives of phenil-quinoline-carbonic acid
PH26521A (en)	1992-08-07	Pharmaceutical formulation
US4322424A (en)	1982-03-30	Crystalline glucoconate salt of m-AMSA and compositions containing same
HU210876A9 (en)	1995-09-28	Arginine derivatives
JPH04211611A (ja)	1992-08-03	腸管外投与しうる、貯蔵安定な、免疫刺激性製剤及びこれを製造する方法
HU183357B (en)	1984-04-28	Process for preparing pharmaceutically acceptable 4'-/9-acridinyl-amino/-methansulphone-m-anizidide salts
JPS6165819A (ja)	1986-04-04	有機ゲルマニウム化合物を含有する薬剤組成物
US4626541A (en)	1986-12-02	Water soluble salt composition of m-AMSA
RU2116081C1 (ru)	1998-07-27	Циклические ингибиторы адгезии
US4946689A (en)	1990-08-07	Concentrated, stabilized cis-diamminedinitratoplatinum solutions for conversion to cisplatin
JP3406334B2 (ja)	2003-05-12	チロシン特異的リン酸化酵素阻害剤及び制癌剤
JP2025137705A (ja)	2025-09-19	トレオスルファンの凍結乾燥物
JP2002080494A (ja)	2002-03-19	新規な抗脱毛ペプチド
JPH03240796A (ja)	1991-10-28	ペプタイド誘導体
JPH09328424A (ja)	1997-12-22	フェニルプロペン酸誘導体
JPH02101014A (ja)	1990-04-12	１−〔（４´‐ヒドロキシ‐２´‐ブテノキシ）メチル〕‐２‐ニトロイミダゾールの凍結乾燥製剤の製造方法